Human vascular smooth muscle cells of diabetic origin exhibit increased proliferation, adhesion, and migration.

PURPOSE Patients with diabetes mellitus (DM) experience progressive macrovascular atherosclerosis and intimal hyperplastic restenosis with increased frequency as compared with nondiabetic patients. These observations suggest that vascular smooth muscle cells (VSMCs) behave in a phenotypically different and more aggressive manner in diabetic patients. In this study, we compared the in vitro rates of proliferation, adhesion, and migration of human VSMCs obtained from diabetic and nondiabetic patients. METHODS Human VSMC cultures were isolated from 23 diabetic patients (9 artery, 14 vein) and 15 nondiabetic patients (9 artery, 6 vein) with extensive lower extremity atherosclerosis. All patients were between 61 and 78 years of age (average: 68.4 years [diabetic]; 67.3 years [nondiabetic]). All diabetic patients had type 2 DM. Vascular specimens were obtained at the time of amputation from infragenicular arteries and during arterial revascularization from saphenous veins. Cells from passages 2 and 3 were assayed for their proliferative capacity with total DNA fluorescence photometry and for adhesion and migration with a modified Boyden chamber. RESULTS The average duration of diabetes was 11.6 +/- 4.1 years. The average number of diabetic complications (retinopathy, neuropathy, nephropathy, coronary artery disease) was 2.8 +/- 0.7 per patient. Diabetic VSMCs exhibited abnormal morphology in cell culture with loss of the normal hill and valley configuration. Proliferation was significantly increased in VSMCs of diabetic origin (156 +/- 57 absorption units) as compared with those of nondiabetic origin (116 +/- 42 absorption units) (P <.001). Diabetic VSMCs demonstrated significantly greater adhesion (63.6 +/- 24 per high-power field vs 37.9 +/- 13 per high-power field; P =.002) and migration (397 +/- 151 per low-power field vs 121 +/- 99 per low-power field; P =.001) rates. CONCLUSIONS Diabetic VSMCs exhibit significantly increased rates of proliferation, adhesion, and migration as well as abnormal cell culture morphology suggestive of abnormal contact inhibition. These observations of human VSMCs in culture are consistent with the increased rate of infragenicular atherosclerosis and the increased rates of restenosis observed clinically in diabetic patients. The atherosclerosis- and intimal hyperplasia-promoting behavior exhibited appears to be intrinsic to the DM-VSMC phenotype and must be considered when designing methods to limit atherosclerosis and intimal hyperplasia in diabetic patients.

[1]  D. Rothenbacher,et al.  Seropositivity to chlamydial lipopolysaccharide and Chlamydia pneumoniae, systemic inflammation and stable coronary artery disease: negative results of a case-control study. , 2000, Journal of the American College of Cardiology.

[2]  K Walsh,et al.  Regulation of smooth muscle cell migration and integrin expression by the Gax transcription factor. , 1999, The Journal of clinical investigation.

[3]  H. Matsuda,et al.  Association of smooth muscle cell phenotypic modulation with extracellular matrix alterations during neointima formation in rabbit vein grafts. , 1999, Journal of vascular surgery.

[4]  V. Gahtan,et al.  Thrombospondin-1 induces activation of focal adhesion kinase in vascular smooth muscle cells. , 1999, Journal of vascular surgery.

[5]  R. Neville,et al.  The additive effects of glucose and insulin on the proliferation of infragenicular vascular smooth muscle cells. , 1998, Journal of vascular surgery.

[6]  J. C. Fox,et al.  Antisense basic fibroblast growth factor gene transfer reduces early intimal thickening in a rabbit femoral artery balloon injury model. , 1998, Journal of vascular surgery.

[7]  M. Fillinger,et al.  Longitudinal comparison of dialysis access methods: risk factors for failure. , 1997, Journal of vascular surgery.

[8]  R. Neville,et al.  Proliferation and extracellular matrix production by human infragenicular smooth muscle cells in response to interleukin-1 beta. , 1997, Journal of vascular surgery.

[9]  G. King,et al.  Vascular dysfunction in diabetes mellitus , 1997, The Lancet.

[10]  R. Neville,et al.  Transforming growth factor β1 inhibits the proliferative effect of insulin on human infragenicular vascular smooth muscle cells , 1997 .

[11]  A. Sidawy,et al.  Phenotypic characterization of human smooth muscle cells derived from atherosclerotic tibial and peroneal arteries. , 1996, Journal of vascular surgery.

[12]  S. Topouzis,et al.  Smooth muscle lineage diversity in the chick embryo. Two types of aortic smooth muscle cell differ in growth and receptor-mediated transcriptional responses to transforming growth factor-beta. , 1996, Developmental biology.

[13]  M. Majesky,et al.  Smooth muscle cell diversity and the extracellular matrix in a rat model of restenosis. , 1996, Puerto Rico health sciences journal.

[14]  K. Kent,et al.  Extracellular matrix proteins are potent agonists of human smooth muscle cell migration. , 1996, Journal of Vascular Surgery.

[15]  B. Sumpio,et al.  Matrix-specific effect of endothelial control of smooth muscle cell migration. , 1996, Journal of vascular surgery.

[16]  M. Cipolla,et al.  Endothelial function and adrenergic reactivity in human type-II diabetic resistance arteries. , 1996, Journal of vascular surgery.

[17]  K. Kent,et al.  Mitogen-activated protein kinase and proliferation of human vascular smooth muscle cells. , 1996, The American journal of physiology.

[18]  M. Fillinger,et al.  Effect of endothelial cells and transforming growth factor-beta 1 on cultured vascular smooth muscle cell growth patterns. , 1994, Journal of vascular surgery.

[19]  G. Evan,et al.  Inhibition of vascular smooth muscle cell proliferation in vitro and in vivo by c-myc antisense oligodeoxynucleotides. , 1994, The Journal of clinical investigation.

[20]  S. Genuth,et al.  The effect of intensive treatment of diabetes on the development and progression of long-term complications in insulin-dependent diabetes mellitus. , 1993, The New England journal of medicine.

[21]  D. Nathan,et al.  Long-term complications of diabetes mellitus. , 1993, The New England journal of medicine.

[22]  P. Chariot.  Images in clinical medicine. Zidovudine myopathy. , 1993, The New England journal of medicine.

[23]  S. Schwartz,et al.  Platelet-derived growth factor promotes smooth muscle migration and intimal thickening in a rat model of balloon angioplasty. , 1992, The Journal of clinical investigation.

[24]  A. Cerami,et al.  Advanced glycosylation end products in tissue and the biochemical basis of diabetic complications. , 1988, The New England journal of medicine.

[25]  R. D'Agostino,et al.  The relative importance of selected risk factors for various manifestations of cardiovascular disease among men and women from 35 to 64 years old: 30 years of follow-up in the Framingham Study. , 1987, Circulation.

[26]  F. Logerfo,et al.  Current concepts. Vascular and microvascular disease of the foot in diabetes. Implications for foot care. , 1984, The New England journal of medicine.